drugset / Trial / NCT07222709
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
RandomizedSequentialTriple-blindBasic science
Summary
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
Timeline
- Start
- 2025-10-27
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABBV-1042 | Unknown | — | Oral |
Indications
No indication recorded.